12:00 AM
Apr 13, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TerbiMed: Phase II data

MedPharm said a short dosing regimen of TerbiMed met the primary endpoint of non-inferiority to Lamisil terbinafine in a German Phase II trial (EudraCT no 2008-002399-92). The...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >